Document Type
Article
Journal Title
Annals of Hematology
Publication Date
2026
Volume
105
Abstract
Epcoritamab, a CD3xCD20 bispecific antibody, resulted in deep, durable responses with a manageable safety profile in patients with relapsed/refractory large B-cell lymphoma (LBCL) in EPCORE® NHL-1 (NCT03625037). We report results from a 3-year follow-up. Adults with relapsed/refractory LBCL received epcoritamab until progressive disease or unacceptable toxicity. The primary endpoint was overall response rate (ORR). Median age was 64.0 years, 39% of patients received prior CAR T-cell treatment, and 75% were refractory to ≥ 2 consecutive lines of treatment. As of May 3, 2024 (median follow-up 37.1 months [range, 0.3-45.5]), ORR was 59% and complete response (CR) rate 41% by investigator assessment. Median duration of response was 20.8 months (95% confidence interval [CI], 13.0-32.0). Median duration of CR was 36.1 months (20.2-not reached [NR]); the longest ongoing CR was > 43 months. Median progression-free survival was 4.2 months (95% CI, 2.8-5.5) in all patients and 37.3 months (26.0-NR) in patients with CR. Median overall survival was 18.5 months (95% CI, 11.7-27.7) in all patients and NR in patients with CR. Of 119 patients evaluable for minimal residual disease (MRD) assessments, 54 (45%) were MRD-negative at any time during the study. Most common adverse events were cytokine release syndrome (51%), fatigue (25%), and pyrexia (25%), with no new safety signals. Grade 1, 2, and 3 infections occurred in 23%, 34%, and 24% of patients, respectively. The durability of responses and prolonged survival in complete responders suggest long-term disease-free survival with epcoritamab in these patients with relapsed/refractory LBCL.
MeSH Headings
Humans, Middle Aged, Male, Female, Aged, Lymphoma, Large B-Cell, Diffuse, Adult, Antibodies, Bispecific, Follow-Up Studies, Aged, 80 and over, Treatment Outcome, Recurrence, Antineoplastic Agents, Immunological, Neoplasm Recurrence, Local
DOI Link
ISSN
1432-0584
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-No Derivative Works 4.0 International License.
Recommended Citation
Karimi, Yasmin H.; Cheah, Chan Y.; Clausen, Michael Roost; Cunningham, David; Farooq, Umar; Feldman, Tatyana; Ghesquieres, Herve; Jurczak, Wojciech; Linton, Kim M.; Phillips, Tycel; Vose, Julie M.; Kim, Won Seog; Jafarinasabian, Pegah; D'Angelo Månsson, Barbara; Soong, David; Steele, Andrew J.; Li, Zhu; Eskelund, Christian W.; Hutchings, Martin; and Thieblemont, Catherine, "Efficacy and Safety of Epcoritamab in Relapsed or Refractory Large B-cell Lymphoma: 3-Year Update from the EPCORE NHL-1 Trial" (2026). Journal Articles: Oncology and Hematology. 22.
https://digitalcommons.unmc.edu/com_onchem_articles/22